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Background: proMMP-9 binds to B-CLL cells and contributes to malignant cell migration/arrest and survival.
Results:TheVPLDTHDVFQsequence from the proMMP-9PEX9domain inhibits41 integrin-mediated proMMP-9-B-CLL
interaction, transendothelial migration, and proMMP-9-induced survival signaling.
Conclusion: The VPLDTHDVFQ sequence is an 41 integrin binding site in proMMP-9 and blocks proMMP-9 effects on
B-CLL cells.
Significance: The identified sequence may be a novel therapeutic target in B-CLL.
We previously showed that pro-matrix metalloproteinase-9
(proMMP-9) binds to B chronic lymphocytic leukemia (B-CLL)
cells and contributes to B-CLL progression by regulating cell
migration and survival. Induction of cell survival involves a non-
proteolytic mechanism and the proMMP-9 hemopexin domain
(PEX9). To help design specific inhibitors of proMMP-9-cell
binding, we have now characterized B-CLL cell interaction with
the isolated PEX9. B-CLL cells bound soluble and immobilized
GST-PEX9, but not GST, and binding was mediated by 41
integrin. The ability to recognize PEX9 was observed in all 20
primary samples studied irrespective of their clinical stage or
prognostic marker phenotype. By preparing truncated forms of
GST-PEX9 containing structural blades B1B2 or B3B4, we have
identifiedB3B4 as the primary41 integrin-interacting region
within PEX9. Overlapping synthetic peptides spanning B3B4
were then tested in functional assays. Peptide P3 (FPGV-
PLDTHDVFQYREKAYFC), a sequence present in B4 or smaller
versions of this sequence (peptides P3a/P3b), inhibited B-CLL
cell adhesion to GST-PEX9 or proMMP-9, with IC50 values of
138 and 279 M, respectively. Mutating the two aspartate resi-
dues to alanine rendered the peptides inactive. An anti-P3 anti-
body also inhibited adhesion to GST-PEX9 and proMMP-9.
GST-PEX9, GST-B3B4, and P3/P3a/P3b peptides inhibited
B-CLL cell transendothelial migration, whereas themutated pep-
tide did not. B-CLL cell incubationwithGST-PEX9 induced intra-
cellular survival signals, namely Lyn phosphorylation and Mcl-1
up-regulation, and this was also prevented by the P3 peptides. The
P3 sequence may, therefore, constitute an excellent target to pre-
vent proMMP-9 contribution to B-CLL pathogenesis.
B-cell chronic lymphocytic leukemia (B-CLL)5 is character-
ized by the accumulation in the peripheral blood of CD5 B
lymphocytes, which progressively infiltrate the bone marrow
and secondary lymphoid tissues (1, 2). As per most cell types,
these migration processes include chemokine receptors, integ-
rins, and matrix metalloproteinases (MMPs) (3–7).
ThemajorMMP found in B-CLL cells is proMMP-9 (92 kDa)
(8), and we and others have shown that (pro)MMP-9 (the pro-
form and/or the active enzyme) plays an important role in
B-CLL transendothelial migration and basement membrane
invasion (9–11). Additionally, the constitutive levels of
(pro)MMP-9 inB-CLL cells are significantly higher than in nor-
mal B-cells, and elevated intracellular levels of (pro)MMP-9
correlate with advanced stage and poor patient survival (9).
Another difference with normal B cells is the consistent pres-
ence of (pro)MMP-9 at the B-CLL cell surface (9, 12). We pre-
viously demonstrated that 41 integrin and a 190-kDa CD44
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variant (CD44v) constitute a docking complex for (pro)MMP-9
in B-CLL cells and that binding of (pro)MMP-9 to this complex
results in inhibition of B-CLL cell migration (12). We also
recently showed that surface-bound proMMP-9 induces
B-CLL cell survival by a non-proteolytic mechanism that
involves Lyn and STAT3 activation and Mcl-1 up-regulation
(13). The proMMP-9 hemopexin domain (PEX9) was required
for (pro)MMP-9 cell binding and subsequent effects, as trun-
cated proMMP-9 forms lacking PEX9 did not bind to B-CLL
cells. Murine PEX9 also bound to these cells and induced sur-
vival, although the receptor involved has not been character-
ized (13).
These previous studies indicate that (pro)MMP-9 contrib-
utes to B-CLL pathogenesis by proteolytic and non-proteolytic
mechanisms andmay constitute a therapeutic target. Given the
lower homology among MMP hemopexin domains compared
with catalytic domains (14), targeting PEX9, in particular its
interaction with cell surface receptors, may be a useful and
more specific approach to prevent B-CLL cell dissemination
and survival. These strategies are already in progress in other
cell systems. For example, phage display analyses have identi-
fied a synthetic peptide (CRVYGPYLLC) that binds to the PEX9
domain, disrupts its binding to 51/V5 integrins in fibro-
sarcoma cells, and inhibits cellmigration (15). Two synthetic pep-
tides (SRPQGPFL and NQVDQVGY) mimicking sequences in
blade 1 and blade 4 of PEX9, respectively, were shown to affect
MMP-9-CD44 interaction, MMP-9 dimerization, and migra-
tion of fibrosarcoma and carcinoma cells (16). A recent in silico
approach has identified two small-molecule compounds that
bind to PEX9 and inhibit tumor growth and metastasis (17).
The isolated murine PEX9 on the other hand was shown to
inhibit MMP-9 activity and invasion of melanoma cells (18),
adhesion and migration of colorectal cancer cells (19), and
angiogenesis and tumor growth in a glioblastoma model
(20).
The interaction between human PEX9 and B-CLL cells has
not been characterized. In this studywe show that humanPEX9
binds to B-CLL cells via 41 integrin and inhibits transendo-
thelial migration. Moreover, we have identified an amino acid
sequence within PEX9 that is involved in PEX9/proMMP-9-B-
CLL cell interaction and functional consequences andmay thus
constitute a therapeutic target in B-CLL.
EXPERIMENTAL PROCEDURES
Patients andCells—Approval was obtained from theConsejo
Superior de Investigaciones Científicas Bioethics Review Board
for these studies. Peripheral blood samples from 20 B-CLL
patients (Table 1) were obtained after informed consent. CD5
B-lymphocytes were purified by Ficoll-Hypaque (Nycomed,
Oslo, Norway) centrifugation and (if needed) negative selection
with anti-CD3-conjugated Dynabeads (Invitrogen). The result-
ing B cell population was 92% CD19 and 72% CD5,
determined on a Coulter Epics XL flow cytometer (Beckman
Coulter, Fullerton, CA). The MEC-1 cell line, established from
a B-CLL patient (23), was obtained from Dr. Enrique Ocio
(Cancer Research Center, Salamanca, Spain) andmaintained in
IMDM medium (Lonza, Basel, Switzerland), 10% fetal bovine
serum. K562 andK562-4 cells were obtained fromDr. Joaquín
Teixido´ (Centro de Investigaciones Biolo´gicas, Madrid) and
cultured in RPMI 1640, 10% fetal bovine serum. Human umbil-
ical vein endothelial cells (HUVEC) were purchased from
Lonza and cultured as reported (10–12).
Antibodies, Reagents, Proteins, and Peptides—Monoclonal
antibodies (mAbs) HP2/1 (anti-4 integrin subunit, function-
blocking), HP1/7 (anti-4 integrin subunit, non-blocking),
HP2/9 (anti-CD44 function blocking), and TS2/16 (anti-1
integrin subunit) were obtained from Dr. Francisco Sa´nchez-
Madrid (Hospital de la Princesa, Madrid, Spain); mAb P1D6
(anti-5 integrin subunit, function-blocking) has been previ-
ously described (10). Rabbit polyclonal antibodies (RpAbs) to
Mcl-1 (sc-819), glutathione S-transferase (GST, sc-459), and
MMP-9 (sc-6841-R) were from Santa Cruz Biotechnology
(Santa Cruz, CA). RpAb to Lyn (#2732) was fromCell Signaling
Technology, Inc. (Beverly, MA); RmAb to phospho-Lyn (Tyr-
396) was from Abcam (Cambridge, UK). mAb to actin (#3853)
was fromSigma). HRP-labeledAbs to rabbit ormouse IgGwere
from Dako (Glostrup, Denmark). Alexa488- and Alexa568-la-
beled Abs were fromMolecular Probes (Eugene, OR). Hyaluro-
nan was from Sigma. CXCL12 and TNF-were from R&D Sys-
tems (Minneapolis, MN). proMMP-9 was isolated fromTHP-1
cell cultures as described (24) or purchased from Calbiochem.
The fibronectin fragment FN-H89, containing the CS1 site (see
below) and vascular cell adhesion molecule-1 (VCAM-1) were
prepared as described (10). Fibronectin-derived synthetic pep-
tides CS1 (41 integrin ligand) and CS3 (inactive control) and
PEX9-derived peptides (Table 2) were synthesized on an
automated multiple peptide synthesizer (AMS 422, ABIMED
Analysen-Technik GmbH, Langenfeld, Germany). Fluoresce-
in-labeled peptides (Table 2) were synthesized using 5(6)-car-
boxyfluorescein (CF, Merck). Spatial localization of peptides
within PEX9 was determined using the Chimera 1.5.3 Program
(RBVI, UCSF, San Francisco, CA).
Construction of Plasmids—A 624-bp sequence correspond-
ing to the hemopexin domain in the full-length humanMMP-9
DNA (cloned in pEGFP-N1) was obtained from Dr. Santos
TABLE 1
Clinical characteristics of B-CLL patients
4 integrin subunit expression was determined for each sample and is indicated as
the percentage of positive cells. ND, not determined.
Patient Sex/Age (y) Stagea 4 (%) CD38/ZAP70b Ig status
1 F/67 B/II 71 /ND ND
2 F/54 B/II 55 /ND Unmutated
3 M/43 A/0 29 / Mutated
4 M/81 A/0 57 /ND Mutated
5 M/56 C/IV 88 / Unmutated
6 M/58 B/II 48 / Unmutated
7 M/67 B/II 20 / Mutated
8 M/69 C/IV 37 / ND
9 F/83 C/IV 74 / Mutated
10 M/70 B/II 75 / Unmutated
11 M/64 A/I 78 / Mutated
12 M/80 A/I 81 / Unmutated
13 M/77 B/I 82 / ND
14 M/83 B/I 43 / Unmutated
15 M/68 B/II 12 / Mutated
16 M/59 C/IV 30 / Unmutated
17 M/85 C/IV 25  / ND Mutated
18 F/73 A/II 76 / Mutated
19 M/60 A/0 37 / Mutated
20 M/48 B/I 20 / ND
a According to Binet et al. (21) and Rai et al. (22) criteria.
b The co-expression of CD38 and ZAP-70 has clinical prognostic value (1, 2).
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Man˜es (Centro Nacional de Biotecnología, Madrid, Spain) (25)
and amplified by PCR. The forward primer 5-GAATTCCCC-
TTTGAGTCCGGTGGACG-3 was engineered with an inter-
nal EcoRI site, and the reverse primer 5-CTCGAGCTAGTC-
CTCAGGGCACTGCA-3 was engineered with an internal
XhoI site. All primers were custom-made by Sigma. Amplifica-
tion of DNAs was performed using AmpliTaqR DNA polymer-
ase (Applied Biosystems, Foster City, CA), and the integrity of
the final construct was confirmed by sequence analysis (Secu-
gen, Madrid). The resultant PCR fragment was then inserted
into the pGEX4T3 vector (GEHealthcare) to generate theGST-
PEX9 DNA. PEX9 mutants were generated using the following
primers: GST-B1B2 forward (5-GAATTCCCCTTTGAGTC-
CGGTGGACG-3) and reverse (5-CTCGAGTCACCTGGG-
CCACGTC-3); GST-B3B4 forward (5-GAATTCAGC-
CGACGTGGCCCAG-3) and reverse (5 CTCGAGC-
TAGTCCTCAGGGCACTGCA-3). All sequences were
confirmed by DNA sequencing.
Expression and Purification of GST and GST Fusion Proteins—
GST and GST fusion proteins were expressed in DH5
Escherichia coli competent cells by induction with isopropyl-1-
thio--D-galactopyranoside. Bacteria cultures were lysed by
sonication in 1.5 M NaCl, 0.5 M Tris, 50 mM Na2EDTA, 10%
Triton, and centrifuged. GSTwas soluble in this buffer and was
purified using a glutathione-agarose matrix (Sigma). The GST
fusion proteins appeared in inclusion bodies and were solubilized
in PBS, 1% sarkosyl. These fusion proteins did not bind to gluta-
thione-agarose under several experimental conditions and were
purified by SDS-PAGE and electroelution. Purity and identity of
electroeluted proteinswas confirmed by SDS-PAGE andWestern
blotting. Purified fusionproteinswere renaturedby extensive dial-
ysis against PBS and proved to be functionally active.
Preparation of the Anti-P3 Peptide Polyclonal Antibody—To
prepare the immunogen, keyhole limpet hemocyanin (Calbio-
chem) dissolved in PBSwas first coupled to sulfo-succinimidyl-
4-(N-maleimidomethyl)cyclohexane-1-carboxylate (1:6000
molar ratio, 1 h, 30 °C). After removing excess reagents by gel
filtration on a PD10 column, keyhole limpet hemocyanin-
succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxy-
late wasmixed with the P3 synthetic peptide at a 1:3000 ratio in
0.1 M phosphate buffer, pH 7.6. The mixture was rotated over-
night at 4 °C in the dark and dialyzed against PBS. A New Zea-
land rabbit was immunized with 250 g of P3-keyhole limpet
hemocyanin Y in complete Freund’s adjuvant by subcutaneous
injections at several regions. Subsequent boosters were with
125 g of antigen in incomplete Freund’s adjuvant at 3-week
intervals. After testing for the presence of antibodies, the whole
blood was obtained by intra-cardiac canaling after two boosters,
serumwas collected, and the anti-P3 Abwas purified using a pro-
tein A-Sepharose column (GE Healthcare). These protocols were
approved by the Consejo Superior de Investigaciones Científicas
Ethics Board. The specificity of the antibody was confirmed by
ELISAassayswith immobilized peptides (8M) or proteins (2M)
using the pre-immune IgG fraction as control.
RNA Interference Experiments—The following siRNA
sequences were custom-made by Ambion (Austin, TX): target-
ing the human 1 integrin subunit, predesigned siRNA
#109879, sense (5-GGAAUGUUCCUAUUUUAACdTT-3);
targeting human CD44, sense (5-GAACGAAUCCUGAAGA-
CAUCUdTT-3) (target bases 1087–1108) (26); control siRNA
sequence, sense (5-AUUGUAUGCGAUCGCAGACdTT-3).
For transfection of B-CLL cells, 2 g of siRNA in 100 l of
RPMI were incubated at room temperature for 10 min with 4.5
l of HiPerfect Transfection Reagent (Qiagen, Hilden, Ger-
many). The mixture was added dropwise to 2  106 cells in
RPMI, 10% FBS, and transfected cells were used after 16 h (1
siRNAs) or 24 h (CD44 siRNAs). Viability of transfected cells
was determined by annexin V and propidium iodide as
described (13).
Cell Adhesion and Soluble Binding Assays—Adhesion assays
were performed on 96-well plates coated with 0.5% BSA or
various concentrations of appropriate proteins. 2  105 pri-
mary B-CLL cells or 1 105 MEC-1 cells were incubated with
1.4 ng/ml 2,7-bis(carboxyethyl)-5(6)-carboxyfluorescein-
acetoxymethyl ester (BCECF-AM, Molecular Probes) for 20
min, suspended in RPMI 1640, 0.5% BSA (adhesion medium),
and added to the coated wells. After 60 min at 37 °C, attached
cells were lysed with PBS, 0.1% SDS and quantified using a
fluorescence analyzer (BMG Labtech, Offenburg, Germany).
For inhibition experiments, cells were incubated (30 min,
37 °C) with appropriate Abs (10g/ml) or peptides (500g/ml,
183–427 M) before adding to the wells. For binding assays in
solution, 1  105 cells were incubated in 100 l of adhesion
medium (for constitutive proMMP-9 expression) or medium
containing the various proteins, peptides, or Abs for 30 min at
4 °C. After washing with ice-coldmedium, cells were incubated
with anti-MMP-9 pAbs (30 min, 4 °C), washed with cold PBS,
and incubated (30 min, 4 °C) with Alexa488-labeled secondary
Abs. Surface-bound proteins were analyzed by flow cytometry.
To calculate IC50 values, cells were incubated with increasing
concentrations of peptides (P3a, P3am,CS1, average range 1.8–
510 M) before the adhesion or soluble binding assays. Values
were determined using the SigmaPlot program (Systat software
Inc., San Jose´, CA).
TABLE 2
Synthetic peptides prepared in this study
P3arv, reversed P3a peptide; P3am, mutated P3a peptide.
Blades B3B4-derived peptides
P1 (621–640)a RGKMLLFSGRRLWRFDVKAQ
P2 (638–657) KAQMVDPRSASEVDRMFPGV
P3 (654–674) PGVPLDTHDVFQYREKAYFC
P4 (672–691) YFCQDRFYWRVSSRSELNQV
P5 (689–707) NQVDQVGYVTYDILQCPED
P3-derived peptides
P3a FPGVPLDTHDVFQYREKb
P3b VPLDTHDVFQb
P3arv KERYQFVDHTDLPVGPF
P3am FPGVPLATHAVFQYREKb
CS1, CS3 peptides
CS1 LVTLPHPNLHGPEILDVPST
CS3 TSGQQPSVGQQMIFEEHGFR
5(6)-Carboxyfluorescein-
labeled peptides
CF-P3a CF-FPGVPLDTHDVFQYREK
CF-P3am CF-FPGVPLATHAVFQYREK
CF-CS1 CF-LVTLPHPNLHGPEILDVPST
CF-CS3 CF-TSGQQPSVGQQMIFEEHGFR
a Numbers in parenthesis indicate the position within proMMP-9 of the amino
acid residues contained in each peptide.
b The two aspartate residues (D) mutated to alanine (A) are highlighted in bold.
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Measurement of Peptide Cell Binding Affinity—1  106
MEC-1 cells in PBS, 1% BSA were incubated at room tempera-
ture with mixtures of 1 M fluorescent peptide (P3a, P3am,
CS1, CS3) and increasing concentrations (1–1000 M) of the
respective unlabeled peptides in a final volume of 100 l. After
60 min, cells were washed and separated by centrifugation, and
the fluorescence remaining in the supernatant (free peptide)
was determined in a fluorescence analyzer. The amount of
bound peptide was determined by subtracting the free peptide
values from the input fluorescence. Binding analyses were per-
formed using the empirical Hill function (27),
B  Bmax
F/F50
n
1 F/F50
n (Eq. 1)
where B is the concentration of bound peptide/cell at a given
free peptide concentration, Bmax is the maximal binding capac-
ity, F is the concentration of free peptide, F50 is Bmax/2, and n is
a Hill coefficient. This analysis allows the estimation of an
apparentKD value (bymeans of the F50 values) and the compar-
ison of the binding properties of the various peptides used in the
study. A MATLAB model script was written for fitting this
model to the binding data.
Transendothelial Migration Assays—0.75  105 HUVEC
were plated on fibronectin-coated (10 g/ml) Transwell filters
(Costar, New York, NY), and confluent monolayers were stim-
ulated with 15 ng/ml TNF- for 16 h before the assay. B-CLL
cells with or without previous incubation with the appropriate
proteins or peptides were added to the HUVECmonolayer and
allowed to migrate toward medium alone or containing 150
ng/ml CXCL12 in the lower chamber. After 24 h at 37 °C, trans-
migrated cells were counted by flow cytometry. Cells that
migrated through HUVECwere expressed as the percentage of
the total number of cells added, also counted by flow cytometry.
Immunofluorescence Analyses—Glass coverslips were coated
with 10 g/ml poly-lysine Lys for 2 h at 37 °C, washed, and
blocked with 1% BSA for 30 min. 5  105 MEC-1 cells with or
without previous incubationwithGST-PEX9were added to the
coverslips and incubated at 37 °C for 1 h. Cells were fixed with
paraformaldehyde, permeabilized with PBS, 0.5% Triton
X-100, and incubated with appropriate primary Abs (5 g/ml)
for 45 min. Cells were washed with ice-cold PBS, 1% BSA and
incubated at room temperature with Alexa488- or Alexa568-
labeled secondaryAbs for 45min. Imageswere acquired using a
LeicaTCS-SP2-AOBS-UVmicroscopewith63 oil immersion
objective. The “Dye-Separation Leica software” was used for
colocalization studies. Image pixels were depicted as dot-plot
representations, where X and Y correspond to the fluorescence
intensity value of each fluorescence channel per pixel. A colo-
calization region was assigned to pixels displaying high levels of
fluorescence for the two analyzed colors.
Western Blotting—B-CLL cells were incubated on 24-well
plates (2.5  106/well) coated with 0.2 M GST, 0.2 M GST-
PEX9, or 60 nM proMMP-9 for either 30 min (p-Lyn) or 24 h
(Mcl-1). For inhibition experiments, cells were incubated (30
min, 37 °C) with 500g/ml peptides before adding to the wells.
Cells were lysed in cold 50 mM Tris, pH 7.4, 100 mM NaCl, 1%
Nonidet P-40, 2 mM MgCl2, 10% glycerol, and protease inhibi-
tors. Cell lysates were resolved by 10% SDS-PAGE and analyzed
by Western blotting as described (13).
Statistical Analyses—Statistical significance of the data was
determined using the two-tailed Student’s t test. A p value of
0.05 was considered significant. Analyses were performed
using the GraphPad InStat v3.05 software (GraphPad Software,
San Diego, CA). All values are expressed as the means S.D.
RESULTS
The Human proMMP-9 Hemopexin Domain Binds to 41
Integrin and Supports Adhesion of B-CLL Cells—Wepreviously
showed that proMMP-9 supports B-CLL cell adhesion via41
integrin andCD44v and that removal of the hemopexin domain
(PEX9) in proMMP-9 significantly impairs this interaction (12).
To establish if PEX9 was indeed responsible for the adhesion-
mediating property of proMMP-9, we prepared a GST-PEX9
fusion protein comprising residues 508–707 of proMMP-9
(HPRDNP004985.2) by E. coli expression (Fig. 1A). After puri-
fication, GST-PEX9 ran as a 50-kDa band in SDS gels, and its
identity was confirmed by Western blotting with an anti-
MMP-9 Ab (Fig. 1B). Recombinant GST (25 kDa) was also pre-
pared by bacteria expression (Fig. 1B) and used as control in
subsequent experiments. Cell adhesion to various concentra-
tions of these proteins was then analyzed. Primary B-CLL cells
and MEC-1 cells attached to GST-PEX9 in a dose-dependent
manner withmaximum average values of 84 and 59% adhesion,
respectively. No adhesion to GST was observed at any concen-
tration tested (Fig. 1C).
To identify the receptor involved in B-CLL cell interaction
with GST-PEX9, we first tested the effect of blocking 41
integrin or CD44 function with antibodies or peptides on cell
adhesion to this substrate. Fig. 1D shows that cell preincubation
with theHP2/1mAb or the CS1 peptide, twowell known inhib-
itors of 4 integrin function (28–30), significantly (p  0.001)
inhibited cell adhesion to GST-PEX9, whereas the control
HP1/7 mAb or the CS3 peptide had no effect. In contrast, the
anti-CD44 mAb HP2/9 did not affect cell adhesion to GST-
PEX9 but efficiently blocked (90% inhibition) B-CLL cell
adhesion to hyaluronic acid (Fig. 1D), confirming that the Ab
was functional. To confirm these results, we transfected B-CLL
cells (samples 11, 17, and 18) with siRNA specific for the 1
integrin subunit or for CD44 or with a control siRNA. Flow
cytometry analyses confirmed the reduction of 1 and CD44
surface expression by 73 and 75%, respectively (shown for two
representative patients in supplemental Fig. S1A). Transfection
efficiency was also validated by Western blot analyses of cell
lysates (shown for patient 18 and quantitated for patients 11
and 18 in supplemental Fig. S1B). Transfected cells were then
tested for adhesion to 0.2 M GST-PEX9. Gene silencing 1
reduced cell adhesion by 84%,whereasCD44 gene silencing had
a minor effect, diminishing cell adhesion by 19% (Fig. 1E). In
contrast, and in agreement with our previous results (12), both
1 and CD44 were required for B-CLL cell adhesion to
proMMP-9 (results not shown).
To further establish that 41 integrin was the receptor for
PEX9, we used K562 cells before and after transfection with the
4 integrin subunit. Parental K562 cells, which lack 41, were
unable to attach to GST-PEX9 but efficiently adhered to
41 Integrin Binding Site in PEX9 as Target in B-CLL
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fibronectin via 51 integrin (Fig. 1F). Transfecting K562 cells
with the 4 integrin subunit resulted in efficient adhesion to
GST-PEX9, which was blocked by the specific 41 inhibitors
HP2/1 and CS1 but not by their corresponding controls (Fig.
1F). Altogether these results indicated that 41 is the primary
adhesion receptor for PEX9 in B-CLL cells.
Soluble proMMP-9 Hemopexin Domain Binds B-CLL Cells
via 41 Integrin—To determine whether B-CLL cells bound
soluble PEX9, as previously observed for soluble proMMP-9
(12), we incubated primary B-CLL cells (three different
patients) or MEC-1 cells with GST-PEX9 in suspension (0.4 or
0.6 M, respectively) and measured the binding by flow cytom-
etry using an anti-MMP-9 antibody. As shown in Fig. 2A for a
representative sample and quantitated for all three patients
studied, primary B-CLL cells bound soluble GST-PEX9,
increasing 2.5-fold the constitutive expression of surface-
bound MMP-9 (12). MEC-1 cells lacked basal MMP-9 surface
expression but also efficiently bound soluble GST-PEX9 (Fig.
2A). In both cases and as observed in the adhesion experiments,
binding was completely inhibited by the HP2/1 mAb and the
CS1 peptide but not by their respective controls (Fig. 2A).
Moreover, gene silencing1 preventedGST-PEX9 cell binding,
reducing the surface expression of (pro)MMP-9 to below the
constitutive levels; CD44 gene silencing, however, had no effect
(supplemental Fig. S1C). GST-PEX9 binding was due to PEX9,
as GST alone was unable to bind B-CLL cells, as analyzed with
an anti-GST antibody, which in turn efficiently detected sur-
face-bound GST-PEX9 (Fig. 2A).
To further confirm these results, we performed immunofluo-
rescence analyses using confocal microscopy. MEC-1 cells
were used for this purpose because, as shown in Fig. 2A, they
lack constitutive expression of surface-bound MMP-9, thus
facilitating detection of exogenously added PEX9. Conse-
quently, in the absence of GST-PEX9, only the 4 or 1
integrin subunits were detected at the cell surface (Fig. 2B).
The addition of GST-PEX9 resulted in a clear colocalization
with both subunits at the cell periphery, as documented by
dot-plot analyses (Fig. 2B). In contrast, GST-PEX9 did not
FIGURE 1. B-CLL cells bind to immobilized GST-PEX9 via 41 integrin. A, a schematic drawing shows the various domains of proMMP-9 and the four
structural blades (B1-B4) of the hemopexin domain (PEX9). The GST fusion protein prepared in this study (GST-PEX9) contained amino acid residues 508–707
of proMMP-9. B, shown is analysis of GST-PEX9 by 10% SDS-PAGE followed by Coomassie Blue staining (CB) or Western blotting (WB) with anti-GST or
anti-MMP-9 polyclonal antibodies. C, BCECF-AM-labeled primary B-CLL cells (patients 5, 7, 10) or MEC-1 cells (3 different experiments) were added to wells
coated with the indicated concentrations of GST or GST-PEX9. After 60 min at 37 °C, attached cells were quantitated using a fluorescence analyzer. D, BCECF-
AM-labeled cells with or without previous incubation with the indicated Abs or peptides were added to wells coated with 0.2M (B-CLL, patients 3, 10, 15) or
0.4M (MEC-1, 3 different experiments) GST-PEX9 or 4M hyaluronic acid (HA), and adhesion was quantitated as explained. E, B-CLL cells (patients 11, 17, 18)
were transfected with control siRNA or siRNA for the 1 integrin subunit or for CD44, labeled with BCECF-AM, and tested for adhesion to 0.2 M GST-PEX9 as
explained. F, 1 105 BCECF-AM-labeled K562 cells, transfected or not with 4 integrin subunit and preincubated or not with the indicated Abs or peptides,
were added to wells coated with either 0.2 M GST, 0.036 M fibronectin (FN), or 0.4 M GST-PEX9. After 60 min, adhesion was quantitated as explained. All
values represent the percentage of the total number of cells added. **, p 0.01; ***, p 0.001.
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colocalize with CD44 (Fig. 2B), in agreement with the cell
adhesion results shown in Fig. 1D.
Characterization of the PEX9 Region Responsible for the
Interaction with 41 Integrin in B-CLL Cells—The PEX9
domain contains a four-bladed-propeller structure (31) as sche-
matically shown in Fig. 3A. To define the PEX9 region involved in
41 integrin binding, we prepared twoGST fusion proteins con-
taining deletions of blades 1–2 (GST-B3B4 protein, proMMP-9
residues 609–707) or blades 3–4 (GST-B1B2protein, proMMP-9
residues 508–613) (Fig. 3B). After purification and SDS-PAGE
analyses (Fig. 3C), purified proteins were tested in adhesion and
soluble binding assays. Fig. 3D shows for MEC-1 cells that the
GST-B1B2 construct was a poor adhesion substrate, whereas the
GST-B3B4 protein supported cell adhesion as effectively as GST-
PEX9. As observed for parental GST-PEX9, adhesion to GST-
B3B4 was completely inhibited by the HP2/1 but not the HP1/7
mAbs(Fig.3D), confirmingthat41 integrinwas thereceptor for
GST-B3B4. In agreement with these results, the soluble GST-
B1B2 protein did not bind to MEC-1 cells, whereas the soluble
GST-B3B4 protein bound 2.9-fold over theMMP-9 basal expres-
sion (Fig. 3E). The anti-GSTAbwas used in these experiments, as
ELISA assays demonstrated that the anti-MMP-9 Ab did not rec-
ognize the GST-B1B2 protein (not shown). GST-B3B4 soluble
bindingwas also inhibited byblocking41 functionwith specific
antibodies or peptides (not shown).
Although the differential adhesion to the GST-B1B2 and
GST-B3B4 constructs was not so obvious for primary B-CLL
cells (average 54% versus 57% adhesion), there were clear and
significant differences in the ability to bind these proteins in solu-
ble form. Fig. 3F shows, for a representative sample out of the four
samples studied, that soluble GST-B1B2 was unable to bind to
B-CLLcells. In contrast, solubleGST-B3B4bound, increasing 2.1-
fold the constitutiveMMP-9 surface expression. Altogether these
results established that thePEX9regionrepresentedbyblades3–4
contained binding sites for 41 integrin.
Identification of anAminoAcid Sequencewithin PEX9Blades
3–4 Recognized by 41 Integrin—To further identify the spe-
cific sequence within PEX9 blades 3–4 that interacted with
41 integrin, we prepared five overlapping synthetic peptides
(P1-P5) spanning residues 621–707 of proMMP-9 (Table 2 and
Fig. 4A) and tested their ability to block cell adhesion to GST-
PEX9. For this initial characterization, peptides were used at
500g/ml, equivalent to 202.8M (P1), 225.2M (P2), 197.5M
(P3), 193.5 M (P4), and 227.3 M (P5) concentrations; thus all
in a similar molar range. Average control adhesion values in
these experiments were 78 and 49% for primary B-CLL and
MEC-1 cells, respectively, and were normalized to 100. Cell
preincubation with the P3 peptide significantly abolished cell
adhesion to GST-PEX9 (55 and 70% average inhibition for
B-CLL and MEC-1, respectively), whereas preincubation with
any of the other peptides did not (Fig. 4B). Narrowing the P3
sequence to FPGVPLDTHDVFQYREK (peptide P3a, 244 M)
or to VPLDTHDVFQ (peptide P3b, 427.4M) also significantly
inhibited cell adhesion toGST-PEX9 (Fig. 4C) or to proMMP-9
(Fig. 4D). This effect was specific as the reverse P3a amino acid
sequence (peptide P3arv, 244M)was inactive (Fig. 4,C andD).
To determine if the two aspartic acid residues of P3a were
important for its function, as observed for many integrin
ligands (32), we mutated the Asp-660 and Asp-663 residues to
alanine (peptide P3am) and tested its effect of cell adhesion. Fig.
4, C and D, show that P3am at 255 M was unable to inhibit
B-CLL cell adhesion to either GST-PEX9 or proMMP-9, thus
establishing that Asp-660 and Asp-663 are involved in 41
binding. The spatial localization of these Asp residues within
PEX9 is depicted in Fig. 4E.
We also studied the functional effect of P3a on41 binding to
other ligands, such asVCAM-1or FN-H89. Fig. 4F shows that P3a
(244M) did not blockMEC-1 cell adhesion to eitherVCAM-1 or
FN-H89, whereas the CS1 peptide (183 M) effectively inhibited
these interactions. In the same experiment, P3a significantly
FIGURE 2. 41 integrin mediates binding of soluble GST-PEX9 to B-CLL
cells. A, primary B-CLL cells (patients 1, 2, 11) and MEC-1 cells (3 different
experiments) with or without previous incubation with the indicated Abs or
peptides were incubated for 30 min with or without GST-PEX9 (0.4 or 0.8 M
for B-CLL or MEC-1 cells, respectively) and analyzed by flow cytometry using
anti-MMP-9 or anti-GST Abs. A representative B-CLL sample (patient 1) out of
the three studied is shown. White areas represent constitutive (pro)MMP-9
expression; gray areas, (pro)MMP-9 expression upon GST-PEX9 binding. Con-
stitutive MMP-9 expression was normalized to 1, and average quantitative
values are shown. *, p  0.05; **, p  0.01. B, MEC-1 cells with or without
previous incubation with 0.6 M GST-PEX9 were added to glass coverslips
coated with 10 g/ml poly-lysine Lys. After 1 h at 37 °C, cells were fixed and
analyzed by confocal microscopy using specific Abs for 4, 1, CD44, or
MMP-9 followed by Alexa488- or Alexa568-labeled secondary Abs. Colocal-
ization of GST-PEX9 with 41 integrin was further demonstrated using dot-
plot analyses. The bar represents 5 m.
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blocked adhesion to proMMP-9 (Fig. 4F) or to GST-PEX9 (not
shown), thus confirming its specificity for these ligands.
We next analyzed if the P3 peptides also blocked cell binding of
soluble GST-PEX9 or proMMP-9. B-CLL cells or MEC-1 cells
were treated with the mentioned M concentration of P3, P3a,
P3b, or P3am peptides followed by incubation with GST-PEX9 or
proMMP-9 and analysis by flow cytometry. Fig. 5, A and B, show
for a representative sample that P3, P3a, andP3b significantly pre-
vented binding of soluble GST-PEX9 to B-CLL or MEC-1 cells.
These peptides also inhibited soluble proMMP-9 binding to
B-CLL cells (Fig. 5, A and B) or MEC-1 cells (95% inhibition, not
shown). As observed for cell adhesion, the P3am peptide had no
effect on either GST-PEX9 or proMMP-9 binding.
A Polyclonal Antibody Raised against the FPGVPLDTHD-
VFQYREKAYFC proMMP-9 Sequence Inhibits B-CLL Cell
Adhesion to PEX9 and proMMP-9—To further confirm the
function of the sequence represented by the P3 peptide, we
prepared a polyclonal antibody by immunizing a rabbit with P3
covalently coupled to keyhole limpet hemocyanin. ELISA anal-
yses demonstrated that this antibody specifically recognized P3
but not P1, P2, P4, or P5 peptides (Fig. 5C). It also recognized
P3a, GST-PEX9 (but not GST), and to a lesser yet specific
extent, proMMP-9. The mutated peptide P3am showed 67%
reduced reactivity against this antibody compared with P3a.
The anti-P3 antibody was next tested in cell adhesion assays.
Average control adhesionvalues in these experimentswere 76 and
39% for PEX9 and proMMP-9, respectively, and were normalized
to 100 (Fig. 5D). Treatment of immobilized GST-PEX9 or
proMMP-9 with anti-P3 antibody (15 g/ml) significantly inhib-
ited B-CLL cell adhesion to both substrata by 45 and 55%, respec-
tively. The preimmune Ig fraction (15 g/ml) had no effect (Fig.
5D). These results confirmed the involvement of the P3 sequence
in proMMP-9 interactionwith B-CLL cells and the accessibility of
this sequence in PEX9 and proMMP-9.
FIGURE 3. Characterization of the PEX9 region that interacts with 41 integrin. A, a ribbon diagram of the monomeric PEX9 domain (PDB entry 1ITV)
shows the position of the four structural blades B1-B4. B, shown is a schematic drawing of the recombinant GST-fusion proteins prepared in this study. The
GST-PEX9 fusion protein contains all four blades (B1-B4), whereas truncated proteins contain either B3B4 (B3B4 protein) or B1B2 (B1B2 protein). C, SDS-gel
analysis of the purified GST-fusion proteins shown in B is visualized by Coomassie Blue staining.D, 1 105 BCECF-AM-labeledMEC-1 cells were added towells
coated with the indicated proteins. After 60 min at 37 °C, attached cells were quantitated using a fluorescence analyzer. Cells with or without previous
incubationwith the indicated Abswere also added towells coatedwith GST-B3B4, and adhesionwas analyzed as explained. 1 105MEC-1 cells (E) or primary
B-CLL cells (patients 9, 10, 17) (F) were incubated for 30min with soluble GST-PEX9, GST-B1B2, or GST-B3B4 and analyzed by flow cytometry using an anti-GST
antibody. A representative sample for B-CLL (patient 17) of the three studied with identical results is shown. White areas represent constitutive (pro)MMP-9
expression; gray areas, (pro)MMP-9 expression upon GST-PEX9 binding. Quantitative values represent the average of three different experiments with tripli-
cate determinations (MEC-1) or three different samples after normalizing constitutive values (Const.) to 1. *, p 0.05.
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Further Characterization of the P3a Sequence Interaction
with B-CLL Cells—Having identified and established the spec-
ificity of the sequence represented by the P3/P3a/P3b peptides,
we carried out dose dependence inhibition analyses. The P3a
and P3am peptides were chosen for these studies and, for com-
parison, the previously described 41 ligand CS1. Fig. 6A
shows that P3a, but not the control P3am, inhibited primary
B-CLL and MEC-1 cell adhesion to PEX9 in a dose-dependent
FIGURE 4. Effect of synthetic peptides derived from the PEX9 domain on B-CLL cell adhesion. A, a ribbon diagram of themonomeric PEX9 domain shows
the location in blades 3–4 of the synthetic peptides P1-P5 prepared in this study (see Table 2). B, BCECF-AM-labeled primary B-CLL cells (patients 8, 14, 19) and
MEC-1 cells (3 different experiments) with or without previous incubations with the indicated peptides (500 g/ml, equivalent to 202.8 M P1, 225.2 M P2,
197.5 M P3, 193.5 M P4, and 227.3 M P5 concentrations) were added to wells coated with 0.2 M (B-CLL) or 0.4 M (MEC-1) GST-PEX9. After 60 min, cell
adhesionwas quantitated as explained. C andD, BCECF-AM-labeled primary B-CLL cells (patients 4, 8, 14) andMEC-1 cells with or without previous incubation
with the indicatedpeptides (500g/ml, equivalent to 197.5MP3, 244MP3a, 427.4MP3b, 244MP3arv, 255MP3amconcentrations)were added towells
coatedwith GST-PEX9 (C) or proMMP-9 (D), and cell adhesionwasmeasured as explained. E, spatial localization of the Asp-660 and Asp-663 residues of the P3
peptide (shown in red) was determined by the Chimera 1.5.3 Program (RBVI, UCSF). F, BCECF-AM-labeledMEC-1 cells with or without previous incubationwith
the indicated peptides (all at 500g/ml; CS1 at 183.0M), were added to wells coated with GST-PEX9 (0.4M), FN-H89 fragment (0.2M), or VCAM-1 (0.1M),
and cell adhesion was analyzed as explained. Values are the average of two different experiments with triplicate determinations and were obtained after
normalizing control values to 100. **, p 0.01; ***, p 0.001.
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manner, with an average IC50 value of 138 and 178 M for pri-
mary B-CLL and MEC-1 cells, respectively. The average IC50
for CS1 in these experiments was 80 M (B-CLL) and 98 M
(MEC-1). P3a inhibition of soluble PEX9 cell binding was also
dose-dependent, resulting in IC50 values of 199 and 114 M for
primary B-CLL and MEC-1 cells, respectively (Fig. 6B). CS1
inhibition in this case rendered IC50 values of 100 and 55 M,
respectively. In both cases, cell adhesion and soluble binding,
the mutated peptide P3am had no effect at any concentration
tested (Fig. 6, A and B).
FIGURE 5. Further effects of P3, P3-derived peptides, and anti-P3 antibodies on B-CLL cells. A, primary B-CLL orMEC-1 cells treated or not for 30minwith
the indicatedpeptides (at the sameMconcentrationsused inFig. 4),were incubatedwith solubleGST-PEX9 (0.4 and0.6M, respectively) orproMMP-9 (60nM).
After 30min, bindingwas analyzed by flow cytometry using an anti-MMP-9 antibody. A representative experiment (patient 18 for B-CLL) is shown.White areas
represent constitutive (pro)MMP-9 expression; gray areas, (pro)MMP-9 expression upon GST-PEX9 binding. Binding of soluble proMMP-9 to MEC-1 cells was
also inhibited by the P3/P3a/P3b peptides and is not shown. B, quantitative values of the soluble binding assays represent the average of four (patients 8, 14,
17, 18; GST-PEX9) or three (patients 14, 17, 18; proMMP-9) B-CLL samples or the average of three different experiments with triplicate determinations (MEC-1).
C, the specificity of the anti-P3 antibody was determined by ELISA assays with the indicated immobilized peptides (8M) or proteins (2 M). Negative control
(Neg. ctrl), average absorbance of peptides or proteins with only secondary antibody. D, BCECF-AM-labeled B-CLL cells (patients 15, 18, 20) with or without
previous incubation with preimmune Ig or anti-P3 antibody were added to wells coated with GST-PEX-9 or proMMP9 and adhesion measured as explained.
*, p 0.05.
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Similar results were obtained for inhibition of cell binding to
proMMP-9 either in immobilized or soluble form. The IC50
values for P3a inhibition of cell adhesion to proMMP-9 were
279 and 109 M for B-CLL and MEC-1 cells, respectively,
whereas these values were 102 and 74 M, respectively, for CS1
(supplemental Fig. S2). Binding of soluble proMMP-9 to cells
was also inhibited by P3a in a dose-dependentmanner andwith
IC50 values of 219 M (B-CLL) and 282 M (MEC-1), whereas
the P3ampeptide had no effect (supplemental Fig. S2). The IC50
values for CS1 in this case were 158 M (B-CLL) and 84 M
(MEC-1). Altogether these results indicated that the inhibitory
activity of the P3a peptide was slightly lower but comparable
with that of the well known 41 ligand CS1.
We next performed direct cell binding analyses using CF-
labeled P3a and P3am peptides as well as CF-CS1 and CF-CS3
(inactive control) for comparison.MEC-1 cells were chosen for
these studies because of their more homogeneous 41 integ-
rin expression compared with primary B-CLL cells. The
CF-P3a andCF-CS1 peptides, but not their corresponding con-
trols CF-P3am or CF-CS3, inhibited cell adhesion to GST-
PEX9 or proMMP-9 as efficiently as their unlabeled counter-
parts (not shown) and thus were considered suitable for these
studies. Fig. 6C shows that both CF-P3a and CF-CS1 peptides
bound to MEC-1 cells in a dose-dependent manner, whereas
the control CF-P3am and CF-CS3 peptides did not. The calcu-
lated apparent KD values obtained from these assays was 282
and 158 M for CF-P3a and CF-CS1, respectively. Saturation
was not reached under the conditions used, probably reflecting
low affinity interactions. Importantly, these results indicated
that the apparentKD for the interaction of P3awithMEC-1 cells
was of the same order as that of the well known 41 integrin
ligand CS1.
Peptides Containing the VPLDTHDVFQ Sequence Block
B-CLLCell TransendothelialMigration and PEX9/proMMP-9-
induced Intracellular Signaling—We and others previously
showed that endogenous (pro)MMP-9 plays a crucial role in
B-CLL cell migration and invasion (9, 10). In this study we
tested whether PEX9 or the P3 peptide modulated the MMP-9
migratory function. B-CLL cells migrated through endothelial
cells in response to CXCL12 with average values of 22–25%
after 24 h, which were normalized to 100. Cell preincubation
with GST-PEX9 or GST-B3B4 significantly inhibited this
migration, whereas GST alone had no effect (Fig. 7A). Impor-
tantly, the synthetic peptides P3 (197.5 M), P3a (244 M), and
P3b (427.4 M) also significantly hampered B-CLL cell migra-
tion (80–85% inhibition, Fig. 7A). As observed for cell adhe-
sion, reversing the amino acid sequence or mutating the Asp-
660 and Asp-663 residues in P3a abolished the inhibitory effect
(Fig. 7A). To confirm that the inhibitory effect of PEX9or theP3
peptides was not due to induction of apoptosis after the 24 h
exposure, we examined cell viability in parallel samples using
annexinV andpropidium iodide (13). This analysis showed that
average viability values (n	 4) were 73, 69, and 77% for control,
GST-PEX9, or P3/P3a peptide-treated cells, respectively, thus
indicating that inhibition ofmigrationwas not due to apoptosis.
We next determined whether the observed peptide inhibi-
tory effect on migration was dose-dependent, as was the case
for inhibition of cell adhesion and soluble binding. As above,
the P3a and P3am peptides and, for comparison, the CS1 pep-
tide were chosen for these studies. Fig. 7B shows that both P3a
and CS1 inhibited B-CLL cell migration in a dose-dependent
manner, with IC50 values of 190 and 97 M, respectively. The
FIGURE 6.Dose-response inhibitory effect and cell binding affinity of the
P3a peptide. Comparison with the CS1 peptide. A, BCECF-AM-labeled pri-
mary B-CLL cells (patients 10, 11, 20) or MEC-1 cells (3 different experiments)
were incubated (30 min, 37 °C) with the indicated concentrations of P3a,
P3am, or CS1 peptides and added to wells coated with 0.2 M (B-CLL) or 0.4
M (MEC-1) GST-PEX9. After 60 min at 37 °C, attached cells were quantitated
using a fluorescence analyzer. Adhesion values in the absence of peptides
were normalized to 100. B, the same B-CLL samples listed in A or MEC-1 cells
were treated for 30 min with the indicated peptide concentrations and incu-
bated with 0.4 M (B-CLL) or 0.6 M (MEC-1) soluble GST-PEX9. After 30 min,
bindingwas analyzedby flowcytometryusingananti-MMP-9 antibody. Bind-
ing in the absence of peptides was normalized to 1. IC50 values for A and
Bwere calculated using the SigmaPlot program. C, increasing concentrations
of the indicated fluoresceinated peptides (CF) were incubated with MEC-1
cells (106/100 l) for 60 min at room temperature. After centrifugation, the
fluorescence of free and bound peptidewas determined as explained. Exper-
imental data were estimated according to the Hill equation using the
MATLAB software. This analysis rendered a Bmax of 960M (P3a) and 1100M
(CS1), Hill n values of 1.8 (P3a) and 1.9 (CS1), and F50 values of 2.45 (P3a) and
2.2 (CS1).
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control P3am peptide had no effect. These results, therefore,
indicated that the IC50 values for P3a and CS1 in these assays
were of the same order of magnitude.
We recently showed that B-CLL cell adhesion to proMMP-9
via41 integrin initiates a survival pathway that includes acti-
vation of the Src-family kinase Lyn and up-regulation of Mcl-1
(13). To determine if the P3a sequence interfered with this sig-
naling, we first studied if cell culturing on GST-PEX9 also acti-
vated Lyn. B-CLL cells from three different patients were incu-
bated on GST, GST-PEX9, or proMMP-9 (positive control) for
30 min, lysed, and analyzed byWestern blotting. Fig. 7C shows
that proMMP-9 and GST-PEX9 increased Lyn phosphoryla-
tion 2.6- and 3.1-fold, respectively, compared with the consti-
tutive values, whereas GST was inactive. Cell preincubation
with the P3a peptide (244 M) completely inhibited this activa-
tion, whereas themutated peptide P3am (255M) had no effect
(Fig. 7C), in agreement with the above results on cell adhesion
and soluble binding.
We also studied the effect of GST-PEX9 onMcl-1 regulation.
B-CLL cells from the same three patients used for the Lyn anal-
yses were cultured on GST, GST-PEX9, or proMMP-9. After
24 h, cells were lysed, and lysates were analyzed by Western
blotting. Fig. 7C shows that incubation onGST-PEX9 increased
the levels of Mcl-1 2.6-fold over the constitutive values, similar
to the effect of proMMP-9 (2.9-fold increase). Cell preincuba-
tion with the P3a peptide completely abolished Mcl-1 up-reg-
ulation (Fig. 7C). As observed for Lyn phosphorylation, the
P3am peptide was inactive. Altogether these results established
that the sequence represented by the P3/P3a/P3b peptides
inhibited B-CLL cell binding to proMMP-9/GST-PEX9 and
subsequent intracellular signaling.
DISCUSSION
Our recent studies have shown that (pro)MMP-9 binds to
B-CLL cells via its hemopexin domain (PEX9) and contributes
to B-CLL pathogenesis by modulating cell migration and sur-
vival (10–13). These studies demonstrated that the survival-
inducing effect does not require MMP-9 catalytic activity but
simply binding to its cell surface receptors (13). In an effort to
help design specific inhibitors that prevent (pro)MMP-9-B-
CLL cell binding, in this report we have biochemically charac-
terized B-CLL cell interaction with the isolated PEX9 domain.
Our major findings are 1) PEX9 supports cell adhesion and
soluble binding to B-CLL cells via 41 integrin and inhibits
B-CLL cell transendothelial migration, 2) synthetic peptides
(P3/P3a/P3b) containing the VPLDTHDVFQ sequence of
PEX9 blade 4 specifically inhibit cell interaction with PEX9 and
proMMP-9, and the two Asp residues in VPLDTHDVFQ are
critical for its function, 3) a polyclonal antibody raised against
P3 blocks B-CLL cell adhesion to PEX9 and proMMP-9, 4) the
P3 peptides inhibit B-CLL cell transendothelial migration and
PEX9/proMMP-9-induced intracellular signaling.
The GST-PEX9 fusion protein prepared in this study, either
immobilized or in soluble form, specifically and efficiently
bound to B-CLL cells, and 41 integrin was the receptor
involved. This was clearly demonstrated by blocking 41
function or gene expression and by using K562 cells with or
without 41 expression. B-CLL cell interaction with isolated
PEX9 thus appears to differ from binding to (pro)MMP-9,
which we previously showed (and confirmed here) to require
41 and CD44v engagement (12). Indeed, CD44H is a well
known receptor for MMP-9 in many cell types (14, 33, 34), and
a recent study using MMP-9-transfected COS-1 cells has
located a CD44 binding region in blade I of the MMP-9
hemopexin domain (16). Our present results show that CD44
was not involved in B-CLL cell adhesion to GST-PEX9 and that
both proteins did not colocalize at the cell surface. Interaction
with one or both receptors may, therefore, depend on the con-
formation (and/or affinity) adopted by PEX9 when present in
(pro)MMP-9 or as an isolated protein. It may also depend on
the cell type studied as, in the above mentioned report (12), we
showed that B-CLL cells differ from other cell types in that
CD44v, but not CD44H, interacts with proMMP-9. Addition-
FIGURE7.Functional effectsofP3peptidesonB-CLLcell transendothelial
migration and proMMP-9/GST-PEX9-induced intracellular signaling.
A, primary B-CLL cells (patients 8, 11, 13, 14, 16) treated or not with the indi-
cated proteins for 30 min were added to the upper chamber of transwell
filters coated with TNF--activated HUVEC. 150 ng/ml CXCL12 was added to
the medium in the bottom chamber, and migrated cells were counted after
24 h by flow cytometry. Average values represent the percentage of the total
number of cells added. B, the same five samples used in Awere preincubated
or not with the indicated peptides at 197.5M P3, 244M P3a, 427.4M P3b,
255 M P3am, and transendothelial migration was measured as explained.
Average values (% of total cells added) are shown. C, 2.5  106 B-CLL cells
from the three patients indicated were added to wells coated with GST,
proMMP-9, or GST-PEX9. Cellswere also treatedwith either 244MP3aor 255
M P3am peptides before adding to GST-PEX9-coated wells. After 30 min
(p-Lyn/Lyn) or 24 h (Mcl-1), cells were lysed, and lysates were analyzed by
Western blotting. Constitutive protein levels (Const) are also shown. Normal-
ized average values of p-Lyn andMcl-1 are shown. *, p 0.05; ***, p 0.001.
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ally, we also recently reported that the survival pathway
induced by proMMP-9 in B-CLL cells apparently involves only
41 integrin (13).
We further show that binding of GST-PEX9 to B-CLL cells
results in inhibition of B-CLL cell transendothelial migration,
as previously observed for murine PEX9 (18–20) and human
PEX2 (theMMP-2 hemopexin domain) (35) in other cell types.
This functionmay have special relevance as naturally occurring
PEX2 has been detected in vivo and produced in vitro upon
proMMP-2 activation with p-aminophenyl-mercuric acetate
(35). It is not known if PEX9 is naturally formed in B-CLL, but
truncated forms of (pro)MMP-9 consisting of a catalytically
active fragment and the hemopexin domain were recently
found in the conditioned medium of breast cancer cells and
produced in vitro by treatment with kallikrein-related pepti-
dase-7 (36).
(pro)MMP-9 has been shown to interact with various integ-
rins in different cell systems, and targeting these interactions
has been the aim of several previous reports. Using phage dis-
play libraries, peptides containing the sequenceDELW, present
in the catalytic domain ofMMP-9 (andMMP-2), were shown to
disrupt the interaction of these MMPs with the I domain of
L2/M2 integrins in THP-1 monocytic cells (37). The
related peptide HFDDDE, also from the catalytic domain,
inhibited in vivo cell extravasation in an acutemyeloid leukemia
xenograftmodel (38). The same authors also reported that pep-
tides containing the CRV motif, a mimic of an integrin activa-
tion epitope, inhibited binding of MMP-9 to the  subunit of
V5 integrin in fibrosarcoma cells (15). In this study we have
used a different approach to define the specific sequences
within the proMMP-9 hemopexin domain involved in 41
binding in B-CLL cells. Using recombinant constructs contain-
ing truncated forms of PEX9 and a series of overlapping syn-
thetic peptides, we have identified the FPGVPLDTHD-
VFQYREKAYFC sequence, located in PEX9 blade 4, as a novel
binding site for 41 integrin. The synthetic peptide P3, con-
taining this sequence, or the related peptides P3a and P3b, rep-
resenting smaller versions of this sequence, completely abro-
gated B-CLL cell transendothelial migration and soluble
binding of GST-PEX9 and proMMP-9 to B-CLL cells. Their
effect on cell adhesion to GST-PEX9 or proMMP-9 was also
dose-dependent and very significant yet partial, suggesting that
other cell binding sitesmay exist within PEX9. Importantly, this
partial effect was sufficient to completely inhibit the survival
signaling pathway induced by cell adhesion to proMMP-9 or
GST-PEX9, as the P3a peptide reduced the up-regulated levels
of p-Lyn and Mcl-1 to constitutive values.
Further evidence for the specificity and integrin ligand func-
tion of the FPGVPLDTHDVFQYREKAYFC sequence came
from two findings; 1) the functional effect of an antibody raised
against the P3 sequence and 2) the fact that mutating the two
Asp residues (Asp-660 andAsp-663) in this sequence abolished
the inhibitory effect of the P3a peptide. It is well established that
Asp residues are key recognition sites for many integrins,
including 41 (29, 30). Moreover, the LDT motif present in
the P3 sequence resembles motifs found in well known 41
ligands, namely LDV and LDA, found in the CS1 region and the
III5 repeat of fibronectin, respectively (29, 39, 40), or the IDS
sequence of VCAM-1 (41). Despite this homology, the P3a pep-
tide, at concentrations proven effective for inhibiting adhesion
to PEX9 or proMMP-9, did not affect cell adhesion to the 41
ligands VCAM-1 or FN-H89. Moreover, our KD and IC50 anal-
yses indicated that the binding of P3a to B-CLL cells is of low
affinity, and this may in fact represent an advantage for specif-
ically targeting (pro)MMP-9-cell interactions (presumably also
of low affinity). In agreement with this, the CS1 peptide, which
in this study showed similar inhibitory and binding activity as
P3a, efficiently inhibited B-CLL cell binding to VCAM-1 or
FN-H89, perhaps reflecting different binding characteristics
that affect more 41/ligand interactions.
Targeting the PEX9 domain is becoming an important focus
for drug development, and a recent study (17) has identified a
small-molecule compound that binds to PEX9 and inhibits car-
cinoma cell migration, proliferation, and metastasis. Using an
in silico docking approach, these authors mapped the binding
site of this compound to the central cavity of PEX9, in fact in
close proximity to the VPLDTHDVFQ sequence identified in
our study. Although it is not known if the compound affects
B-CLL cells, this study strongly supports our present findings.
Moreover, VPLDTHDVFQ, in contrast to previously identified
sites located in the MMP-9 catalytic region, is not present in
other MMPs as a BLAST analysis revealed. Additionally, we
show in our study that this sequence was effective in all B-CLL
cases studied, irrespectively of the clinical stage or prognostic
marker expression. All these findings make the VPLDTHD-
VFQ sequence identified here an excellent target to specifically
block (pro)MMP-9-B-CLL cell interactions and subsequent
intracellular events that contribute to B-CLL progression.
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